ES2666850T3 - Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida - Google Patents

Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida Download PDF

Info

Publication number
ES2666850T3
ES2666850T3 ES12719487.6T ES12719487T ES2666850T3 ES 2666850 T3 ES2666850 T3 ES 2666850T3 ES 12719487 T ES12719487 T ES 12719487T ES 2666850 T3 ES2666850 T3 ES 2666850T3
Authority
ES
Spain
Prior art keywords
interferon
week
dose
patient
titration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12719487.6T
Other languages
English (en)
Spanish (es)
Inventor
Aaron Deykin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Application granted granted Critical
Publication of ES2666850T3 publication Critical patent/ES2666850T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
ES12719487.6T 2011-03-15 2012-03-15 Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida Active ES2666850T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161452807P 2011-03-15
US201161476930P 2011-04-19 2011-04-19
US201161476930P 2011-04-19
PCT/US2012/029201 WO2012125809A1 (en) 2011-03-15 2012-03-15 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Publications (1)

Publication Number Publication Date
ES2666850T3 true ES2666850T3 (es) 2018-05-08

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12719487.6T Active ES2666850T3 (es) 2011-03-15 2012-03-15 Procedimiento para reducir los síntomas similares a gripe asociados a la administración intramuscular de interferón usando un régimen de dosificación creciente de titulación rápida

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
EP3092305B1 (en) 2014-01-09 2023-08-02 Kyushu University, National University Corporation Method of producing microglial cells
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
WO2022069250A1 (en) * 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp ２室型プレフィルドシリンジ
US8932265B2 (en) * 2003-01-30 2015-01-13 Becton, Dickinson And Company Holder with safety shield for a drug delivery device
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
CA2846786C (en) * 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
EP2686002B1 (en) 2018-01-24
MX359947B (es) 2018-10-17
NZ712273A (en) 2016-09-30
HUE036931T2 (hu) 2018-08-28
KR20140038383A (ko) 2014-03-28
IL228425A0 (en) 2013-12-31
AU2012229104B2 (en) 2017-03-16
SG193446A1 (en) 2013-10-30
DK2686002T3 (en) 2018-04-30
EA201301024A1 (ru) 2014-03-31
BR112013023609A2 (pt) 2016-12-06
NZ616536A (en) 2015-10-30
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
SI2686002T1 (en) 2018-06-29
AU2012229104A1 (en) 2013-10-03
US20170360890A1 (en) 2017-12-21
US9198955B2 (en) 2015-12-01
ZA201306933B (en) 2016-07-27
IL228425A (en) 2017-08-31
EP2686002A1 (en) 2014-01-22
PT2686002T (pt) 2018-04-23
US20120237479A1 (en) 2012-09-20
JP6522069B2 (ja) 2019-05-29
JP6279905B2 (ja) 2018-02-14
WO2012125809A1 (en) 2012-09-20
US20160101157A1 (en) 2016-04-14
CY1120176T1 (el) 2018-12-12
JP2014508174A (ja) 2014-04-03
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
LT2686002T (lt) 2018-05-10
KR102050339B1 (ko) 2019-11-29
MX2013010507A (es) 2014-04-30
HRP20180621T1 (hr) 2018-07-27
CA2846786C (en) 2022-05-17
US10500254B2 (en) 2019-12-10
CN103702680A (zh) 2014-04-02
US20250276042A1 (en) 2025-09-04
SMT201800221T1 (it) 2018-07-17
EA028448B1 (ru) 2017-11-30
PL2686002T3 (pl) 2018-10-31
JP2018030847A (ja) 2018-03-01
US20220280610A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
US20250276042A1 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
ES2417061T3 (es) Formulaciones líquidas de interferón estabilizadas, exentas de hsa
EP2533634B1 (en) Neuroprotection in demyelinating diseases
CN102458476A (zh) 用于治疗多发性硬化症的组合物及方法
JP6820841B2 (ja) ペグ化インターフェロンのための投薬計画
ES2991384T3 (es) Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C)
US12187788B2 (en) Methods for treating atopic dermatitis and related disorders
Arasiewicz et al. Successful treatment of a child’s generalized pustular psoriasis with adalimumab in combination with low-dose acitretin
IL296620A (en) Methods for treating atopic dermatitis and related disorders
HK1192473B (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1192473A (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ712273B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
NZ616536B2 (en) Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8178083B2 (en) Treatment of optic neuritis
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
Jose Sa et al. Etiopathogenesis, classical immunotherapy and innovative nanotherapeutics for inflammatory neurological disorders